federal research data in which people were asked about their GLP-1 prescriptions.Results showed that among people without diabetes, GLP-1 drug use rose from 0.1% of the population in 2018 to 0.4% in 2022.That doesnt seem like a lot, amounting to an estimated 854,000 Americans without diabetes using GLP-1 drugs to lose weight in 2022, but the drugs are costly, and can run close to $1,000 or more a month, researchers found.As a result, estimated annual spending on GLP-1 drugs among non-diabetics rose from $1.6 billion between 2018 and 2021 to $5.8 billion in 2022, the study showed.On average, the drugs cost $1,540 per prescription, but patients paid an average of just under $35 out-of-pocket for each prescription.The study provides the first characterization of nationwide GLP-1 use and spending among individuals without diabetes to guide ongoing debates about balancing the sustainability of health care spending against improving accessibility and affordability of GLP-1 medications going forward, researchers concluded.More informationHarvard Medical School has more on insurance coverage for GLP-1 drugs.SOURCE: Annals of Internal Medicine, March 31, 2025 .What This Means For YouPeople who are obese should talk to their doctor about whether they qualify for insurance coverage for a GLP-1 drug..Sign up for our weekly HealthDay newsletter
Candida albicans possesses two distinct morphological forms as yeast and mycelium and this phase transition plays a major role in its pathogenicity (Prasad, 1991)
As such, Shirani continued, prescribing drugs such as metformin or pioglutazone may reduce disease activity revealed through MRI and may influence pro-inflammatory T-cell response
The Role of Zonulin In Intestinal Permeability This article provides an overview of the protein Zonulin (function, structure, location)
271 , E458E464 (1996)
